Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials

Mar 18, 2025Diabetes care

Early Blood Sugar or Weight Loss with Tirzepatide and Metabolic Results in People with Type 2 Diabetes

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

50% of participants showed an early glycemic response with a significant reduction in HbA1c of -2.6% at week 40/42.

Early responders in fasting serum glucose (FSG) were generally younger and had higher glycemic levels and lower weight at baseline.
31% of early weight responders had lower glycemic parameters and weight at baseline, with a higher proportion being women and White.
Participants who responded early in FSG or weight achieved greater reductions in HbA1c and weight compared to non-responders.
Both groups experienced improvements in blood pressure and lipid profiles, with non-responders also showing clinically meaningful reductions.
The incidence of gastrointestinal adverse events was mild to moderate and generally similar between early and non-early responders.

AI simplified

OBJECTIVE: To evaluate late (week 40 or 42; hereafter, week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at week 4) or weight response (<5% or ≥5% weight reduction at week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials.

RESEARCH DESIGN AND METHODS: This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively.

RESULTS: Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline, and a greater percentage were women and White. Early versus nonearly responders in FSG or weight achieved better HbA1c (-2.6% vs. -2.0% or -2.5% vs. -2.2%, respectively) and weight (-11% vs. -10% or -15% vs. -8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile. Nonearly responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild to moderate events) decreased over time and was, in general, comparable between early and nonearly responders.

CONCLUSIONS: Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text ↗

Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief